Company intelligence / Profile preview

Bright Green Grown Innovation

Grants, New Mexico, United States

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Bright Green is conditionally authorized by the DEA, preparing to produce GMP cannabis-derived APIs and plant-based drugs for pharmaceutical research and ingredient markets; major greenhouse and facility buildout underway in New Mexico. No independent clinical results as a drug developer; focus is on API and ingredient supply.

Therapeutic areas: OtherNeurologyPsychiatry
Modalities: Plant-derived Active Pharmaceutical Ingredients (APIs)Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Dalsem Complete Greenhouse Projects B.V. (greenhouse construction)Universal FAB (facility engineering)Nordic Supreme (cannabis genetics supply, agreement in negotiation)Asia Capital Pioneers Group (USCIS EB-5 investment partnership)

Beyond the preview

Go deeper on Bright Green Grown Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Green Grown Innovation.

Explore the full profile